MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./280/0.1/21.03.25 Stock

Warrant

DE000MG0Y1L3

Real-time Bid/Ask 11:40:57 2024-05-21 EDT
0.52 EUR / 0.56 EUR +1.89% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./280/0.1/21.03.25
Current month-13.11%
1 month-20.90%
Date Price Change
24-05-21 0.52 -1.89%
24-05-20 0.53 +1.92%
24-05-17 0.52 -5.45%
24-05-16 0.55 -5.17%
24-05-15 0.58 +5.45%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 04:14 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN MG0Y1L
ISINDE000MG0Y1L3
Date issued 2024-03-27
Strike 280 $
Maturity 2025-03-21 (304 Days)
Parity 10 : 1
Emission price 0.82
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.12
Lowest since issue 0.51
Spread 0.04
Spread %7.41%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW